From: Simmons, Sandra

Sent: Friday, May 30, 2014 10:41 AM

To:Simmons, WilliamCc:Napoli, Thomas

Subject: RE: Reminder: CSOPs Past Due for Periodic Review - Sales & Marketing

Attachments: RE: Reminder: CSOPs Past Due for Periodic Review - Sales & Marketing; CSOP

011-004,_Suspicious_Orders_of_Controlled_Drugs.pdf

CSOP was reviewed by me on May 2^{nd} . I entered Will as a reviewer. I am not sure if you reviewed the document. At that time no changes were made and the document was approved. All of the emails back and forth is to find our who is the HotDox approver. If you want them to reject the document and sent it back for another review I can do this.

I am available both days, let me know when you are available.

Thanks

Sandra Simmons
Manager Support Services
Actavis Pharma, Inc.
Morris Corporate Center III
400 Interpace Parkway Bldg A
Parsippany, NJ 07054
(T) 862-261-7072
(C) 973-997-2118

email: sandra.simmons@actavis.com

From: Simmons, William

Sent: Friday, May 30, 2014 11:43 AM

To: Simmons, Sandra **Cc:** Napoli, Thomas

Subject: FW: Reminder: CSOPs Past Due for Periodic Review - Sales & Marketing

Hi Sandy -

Can we sit down next week sometime to discuss CSOP 011-004 Suspicious Orders of Controlled Drugs.

Tom and I have some ideas and I think with the position that you are trying to fill we can make this a more robust document in terms of how we handle SOMS.

I'm traveling Mon-Tues but will be available the rest of the week.

Thanks,

Will

From: Woods, Mary

Sent: Friday, May 30, 2014 8:43 AM **To:** Leplar, Chloe Gyda; Napoli, Thomas **Cc:** Simmons, Sandra; Simmons, William

Subject: RE: Reminder: CSOPs Past Due for Periodic Review - Sales & Marketing

PLAINTIFFS TRIAL EXHIBIT P-08372_00001

I would suggest that Sarosh may be appropriate to start with, and he can determine if this should be escalated to Molly. Thank you.

Best Regards,

Mary J. Woods

Executive Director, US Order Management Actavis Pharma, Inc. Morris Corporate Center III 400 Interpace Parkway Parsippany, New Jersey 07054 **862-261-8701 (C) 951-316-3616** ⊠mary.woods@actavis.com

www.actavis.com



Please note that this e-mail and its attachments are intended for the named addressee only and may contain information that is confidential and privileged. If you have by coincidence or mistake or without specific authorization received this e-mail and its attachments we request that you notify us immediately that you have received them in error, uphold strict confidentiality and neither read, copy, nor otherwise make use of their content in any way Please note that the sender of this email and its attachments is solely responsible for its content if it does not concern the operations of Actavis Group or its subsidiaries.

From: Leplar, Chloe Gyda

Sent: Wednesday, May 28, 2014 9:10 AM To: Napoli, Thomas; Woods, Mary Cc: Simmons, Sandra; Simmons, William

Subject: RE: Reminder: CSOPs Past Due for Periodic Review - Sales & Marketing

Hi all,

Please forgive me if I ask then, who is the QA approver of this document? This is basically what I need to know, we in the documentation department verify that the correct QA approver is assigned to each section in Livelink. This document is in section 011 and we had Wanda Eng in our matrix for QA approver for section 011. Wanda says she is part of post marketing so should not approve.

Mary, you say this document has move to the supply chain side of the business. Would Molly Martin or Sarosh Printer be QA approvers?

Sorry for my confusion.

Kind regards, Chloe

Chloe Gyda Leplar

Documentation Specialist Senior

Actavis

P-08372 00002

Reykjavikurvegur 76-78, 220 Hafnarfjordur Iceland T +354 535 7484 E <u>ChLeplar@actavis.is</u> www.actavis.com





From: Tom P Napoli [mailto:Tom.Napoli@actavis.com]

Sent: 28. maí 2014 13:00

To: Mary J Woods

Cc: Sandra I Simmons; William Simmons; Chloe Gyda Leplar

Subject: RE: Reminder: CSOPs Past Due for Periodic Review - Sales & Marketing

I am in total agreement, Mary!

From: Mary J Woods

Sent: Wednesday, May 28, 2014 8:54 AM

To: Chloe Gyda Leplar

Cc: Sandra I Simmons; Tom P Napoli; William Simmons

Subject: FW: Reminder: CSOPs Past Due for Periodic Review - Sales & Marketing

Hi Chloe,

The SOP is part of US Order Management. I believe that when the department was moved from the commercial side of the business to the supply chain side, the signatories were not moved. Sandra Simmons owns the initial document, she reports to me, and the DEA Affairs team would be the final approver from the operational aspect. It should be Sandra Simmons who submits, sent to me to review and approve, and then to Tom Napoli (or his designee) for final approval operationally.

Tom, are you in agreement?

Thanks

Best Regards,

Mary J. Woods

Executive Director, US Order Management Actavis Pharma, Inc.
Morris Corporate Center III
400 Interpace Parkway
Parsippany, New Jersey 07054
862-261-8701 (C) 951-316-3616

⊠mary.woods@actavis.com

www.actavis.com



Please note that this e-mail and its attachments are intended for the named addressee only and may contain information that is confidential and privileged. If you have by coincidence or mistake or without specific authorization received this e-mail and its attachments we request that you notify us immediately that you have received them in error, uphold strict confidentiality and neither read, copy, nor otherwise make use of their content in any way Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis Group or its subsidiaries.

From: Baran, Nancy

Sent: Friday, May 23, 2014 6:09 PM

To: Woods, Mary **Cc:** Leplar, Chloe Gyda

Subject: FW: Reminder: CSOPs Past Due for Periodic Review - Sales & Marketing

Hi Mary,

I researched this CSOP and you are the owner, so I thought that perhaps putting you in touch would Chloe may give her exactly what she is looking for. I didn't think of you upon first hearing "SOM" only because she was looking for a "Quality" approver. I'm not sure if you are the person, but please let us know.

Thanks, Nancy

Nancy Baran

Director, Customer Relations Actavis Pharma, Inc. Morris Corporate Center III 400 Interpace Parkway Parsippany, NJ 07054

862-261-7592 (office)

908-425-1380 (cell)

nbaran@actavis.com





From: Leplar, Chloe Gyda

Sent: Tuesday, May 13, 2014 11:19 AM

To: Baran, Nancy

Subject: RE: Reminder: CSOPs Past Due for Periodic Review - Sales & Marketing

Thanks Nancy, I appreciate that!

Chloe Gyda Leplar

Documentation Specialist Senior

Actavis

Reykjavikurvegur 76-78, 220 Hafnarfjordur

Iceland





From: Nancy Baran [mailto:NBARAN@actavis.com]

Sent: 13. maí 2014 13:09

To: Napoleon D Clark; Chloe Gyda Leplar; Wanda Eng

Cc: Anke von Harpe

Subject: Re: Reminder: CSOPs Past Due for Periodic Review - Sales & Marketing

Just taking off on a flight. I don't know, but would be willing to ask around. I will get back with you. Tx

Nancy

From: Napoleon D Clark

Sent: Tuesday, May 13, 2014 09:06 AM

To: Chloe Gyda Leplar; Wanda Eng; Nancy Baran

Cc: Anke von Harpe

Subject: RE: Reminder: CSOPs Past Due for Periodic Review - Sales & Marketing

Sorry Chloe: but I have no idea who the Quality approver is.

NaP

Napoleon D. Clark

Exec. Director of Marketing, Generics

Actavis

Morris Corporate Center III 400 Interpace Parkway Parsippany, NJ 07054

Napoleon.Clark@Actavis.com

P: 862-261-7268 F: 862-261-7944

From: Chloe Gyda Leplar

Sent: Tuesday, May 13, 2014 9:04 AM

To: Wanda Eng; Nancy Baran; Napoleon D Clark

Cc: Anke von Harpe

Subject: RE: Reminder: CSOPs Past Due for Periodic Review - Sales & Marketing

Hi Wanda,

Thanks for your suggestions. But we are specifically looking for the Quality approvers and Nancy and Napoleon are not in Quality.

Nancy, Napoleon,

Do you have suggestions for Quality approvers for Sales and Marketing CSOPs in Livelink (section 011)? The document we are looking at here is CSOP 011-004, Suspicious Orders of Controlled Drugs.

Many thanks

Chloe

Chloe Gyda Leplar

Documentation Specialist Senior

Actavis
Reykjavikurvegur 76-78, 220 Hafnarfjordur
Iceland
T +354 535 7484
E ChLeplar@actavis.is



www.actavis.com



From: Wanda Eng

Sent: 12. maí 2014 15:07 **To:** Chloe Gyda Leplar **Cc:** Nancy Baran

Subject: RE: Reminder: CSOPs Past Due for Periodic Review - Sales & Marketing

Let's try Napoleon Clark in Sales & Marketing or Nancy Baron in Customer Service.

From: Chloe Gyda Leplar

Sent: Monday, May 12, 2014 10:45 AM

To: Wanda Eng **Cc:** Anke von Harpe

Subject: RE: Reminder: CSOPs Past Due for Periodic Review - Sales & Marketing

HI Wanda,

Please advise who should be the QA approver for section 011 in Livelink in your place.

Many thanks

Chloe

Chloe Gyda Leplar

Documentation Specialist Senior

Actavis

Reykjavikurvegur 76-78, 220 Hafnarfjordur

Iceland

T+354 535 7484

E ChLeplar@actavis.is

www.actavis.com





From: Wanda Eng

Sent: 12. maí 2014 14:40 **To:** Chloe Gyda Leplar

Subject: RE: Reminder: CSOPs Past Due for Periodic Review - Sales & Marketing

I am not part of Sales & Marketing. Please change.

I am part of post marketing.

From: Chloe Gyda Leplar

Sent: Monday, May 12, 2014 10:24 AM

To: Wanda Eng

Subject: RE: Reminder: CSOPs Past Due for Periodic Review - Sales & Marketing

Dear Wanda,

You are getting these because you are the QA signer for section 011 (Sales and Marketing) in Livelink in our signature matrix for CSOPs. This matrix was established in Cori Pino's old department.

Is this not correct? Please advise.

Many thanks

Chloe

Chloe Gyda Leplar

Documentation Specialist Senior

Actavis

Reykjavikurvegur 76-78, 220 Hafnarfjordur

Iceland

T+354 535 7484

E ChLeplar@actavis.is

www.actavis.com





From: Wanda Eng

Sent: 12. maí 2014 14:12 To: Chloe Gyda Leplar

Subject: RE: Reminder: CSOPs Past Due for Periodic Review - Sales & Marketing

Dear Chloe

Why am I part of the Author/Management periodic review for CSOP 011-044, Suspicious Orders of Controlled Drugs . I'm not in the Sales & Marketing Department.

Do you need to re-direct your request?

Wanda Eng

Executive Director Global Compliance

Actavis plc
Morris Corporate Center III
400 Interpace Parkway
Parsippany , NJ 07054
United States
T 862-261-7139
E WENG@actavis.com
www.actavis.com





From: Chloe Gyda Leplar

Sent: Monday, May 12, 2014 9:54 AM **To:** Sandra I Simmons; Wanda Eng

Cc: Anke von Harpe; Kristin Petursdottir; Rosemary Cunningham

Subject: Reminder: CSOPs Past Due for Periodic Review - Sales & Marketing

Attention: Sales & Marketing CSOP Author/Management

This CSOPs is past due for its Biennial Periodic Review. This is a compliance issue. As stated in CSOP 001-129, "Corporate Standard Operating Procedures and Corporate Forms" - CSOPs must be reviewed every two years.

- **1)** If the CSOP **needs to be revised**, initiate and complete a Livelink Change Workflow as soon as possible. Refer to CTMAN 130-002 for Livelink help.
- **2)** If the CSOP **does NOT need to be revised**, initiate and complete a Livelink Periodic Review Workflow as soon as possible. Refer to CTMAN 130-002 for Livelink help.

Your prompt attention to this matter is appreciated.

If you have already initiated a Livelink workflow, it will be indicated in yellow in the table(s) below.

We thank you for your efforts in updating these procedure(s).

Past Due:

Document Number	CSOP Title	Last Date Reviewed	Author/Contact Name	Manager/QA	Status
CSOP 011-004	Suspicious Orders of Controlled Drugs	07/19/2011	Sandra I Simmons	Wanda Eng	

Chloe Gyda Leplar

Documentation Specialist Senior

Actavis
Reykjavikurvegur 76-78, 220 Hafnarfjordur
Iceland
T +354 535 7484
E ChLeplar@actavis.is
www.actavis.com





This message and its attachments are intended for the named addressee only, and may contain confidential, proprietary or legally privileged information. No confidentiality or privilege is waived or lost by any mistransmission. If you have by coincidence or mistake received this email and its attachments, please immediately delete it and all copies of it from your system, destroy any hard copies of it and notify the sender. You must not, directly or indirectly, use, disclose, distribute, print or copy any part of this message or its attachments if you are not the intended recipient. Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis or its affiliates.

From: Simmons, Sandra

Sent: Wednesday, April 30, 2014 11:34 AM

To: Leplar, Chloe Gyda; Eng, Wanda; Simmons, William

Cc: Anke von Harpe; Petursdottir, Kristin; Rosemary Cunningham

Subject: RE: Reminder: CSOPs Past Due for Periodic Review - Sales & Marketing

Hi Chloe and Wanda,

Initiated Periodic Review Request (PR-2288049).

Will, you are assigned to Review.

Thanks

Sandra Simmons
Manager Support Services
Actavis Pharma, Inc.
Morris Corporate Center III
400 Interpace Parkway Bldg A
Parsippany, NJ 07054
(T) 862-261-7072
(C) 973-997-2118

email: sandra.simmons@actavis.com

From: Chloe Gyda Leplar

Sent: Friday, April 11, 2014 7:58 AM **To:** Sandra I Simmons; Wanda Eng

Cc: Anke von Harpe; Kristin Petursdottir; Rosemary Cunningham

Subject: Reminder: CSOPs Past Due for Periodic Review - Sales & Marketing

Attention: Sales & Marketing CSOP Author/Management

This CSOPs is past due for its Biennial Periodic Review. This is a compliance issue. As stated in CSOP 001-129, "Corporate Standard Operating Procedures and Corporate Forms" - CSOPs must be reviewed every two years.

- 1) If the CSOP needs to be revised, initiate and complete a Livelink Change Workflow as soon as possible. Refer to CTMAN 130-002 for Livelink help.
- **2)** If the CSOP **does NOT need to be revised**, initiate and complete a Livelink Periodic Review Workflow as soon as possible. Refer to CTMAN 130-002 for Livelink help.

Your prompt attention to this matter is appreciated.

If you have already initiated a Livelink workflow, it will be indicated in yellow in the table(s) below.

We thank you for your efforts in updating these procedure(s).

Past Due:

1

Document Number	CSOP Title	Last Date Reviewed	Author/Contact Name	Manager/QA	Status
CSOP 011-004	Suspicious Orders of Controlled Drugs	07/19/2011	Sandra I Simmons	Wanda Eng	

Chloe Gyda Leplar


Documentation Specialist Senior

Actavis
Reykjavikurvegur 76-78, 220 Hafnarfjordur
Iceland
T +354 535 7484
E ChLeplar@actavis.is
www.actavis.com





This message and its attachments are intended for the named addressee only, and may contain confidential, proprietary or legally privileged information. No confidentiality or privilege is waived or lost by any mistransmission. If you have by coincidence or mistake received this email and its attachments, please immediately delete it and all copies of it from your system, destroy any hard copies of it and notify the sender. You must not, directly or indirectly, use, disclose, distribute, print or copy any part of this message or its attachments if you are not the intended recipient. Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis or its affiliates.



PAGE: 1 of 5 EFFECTIVE DATE: 07/19/2011

PURPOSE:

To assure distribution of controlled drugs is monitored for excessive use by an individual location using the DEA number as the identifier.

SCOPE:

This procedure applies to all controlled drugs distributed by Watson Laboratories, Inc. and its Subsidiaries.

DOCUMENT REFERENCES:

<u>Document Number</u>	<u>Document Title</u>
CTMAN 080-045	License Entry and Maintenance
CTMAN 080-203	Order Processing


DEFINITIONS:

•	DEA	Drug Enforcement Administration – A component of the Justice Department whose regulations.
•	SOMS	Suspicious Order Monitoring System

PROCEDURE:

Responsibility	<u>Action</u>			
	1.0	Process for Suspicious Orders of Controlled Drugs		
General	1.1	The SAP system compiles a past history of controlled substance drug product orders by each customer to establish a normal order size and order frequency. This is accomplished through the normal Sales Order process (see CTMAN 080-203 Order Processing, for details on this process).		
DEA Affairs	1.2	The DEA Affairs Department determines the SOMS Multiplier Table.		
		1.2.1 See CTMAN 080-045, License Entry and Management for description of system functionality with regards to the establishment of SOM levels, as well		

as how to access this information.



PAGE: 2 of 5 EFFECTIVE DATE: 07/19/2011

Responsibility Action

Master Data Administrator


- 1.3 If a processed order generates a SOMS excessive order flag in SAP (See CTMAN 080-045, License Entry and Maintenance), due to more frequent or larger than the normal order pattern, Master Data Administrator will generate a Suspicious Order Monitoring System (SOMS) form.
- 1.4 The Master Data administrator will review the SOMS form, and then, if warranted, contact the customer to confirm the quantity ordered and verify the reason for a larger or more frequent order.
- 1.5 Once this SOMS form is analyzed, the SOMS form is signed and marked with a reason code by the Master Data Administrator and if necessary submitted to the Manager for review, and signature.
- 1.6 The Master Data Administrator will be responsible to ensure that pending sales orders on hold due to suspicious order (SOMS) violation are investigated.
- 1.7 The Master Data Administrator will release pending orders due to SOMS violations by releasing the order in full, canceling the order, or reducing the quantity, per SOMS procedure.
- 1.8 If the SOMS violation cannot be resolved by research and justification, canceling the order or reducing the quantity, the Master Data administrator will escalate the suspicious order to the next level.
- 1.9 If a valid reason (based on objective criteria) does not exist, the order will be deemed as an order of interest or a suspicious order and held for further review. Orders deemed as an order of interest or as suspicious, will be forwarded to the DEA Affairs Department for further review.

DEA Affairs

1.10 Upon confirmation that the order is suspicious, the DEA Affairs Department will be responsible for reporting the order to the Drug Enforcement Administration and the applicable State Board of Pharmacy. Department of Regulatory Affairs will also report the incident to FDA within three business days.

Master Data Administrator

1.11 File a copy of the SOMS form, along with any back up documentation, in the suspicious order record file.




PAGE: 3 of 5 EFFECTIVE DATE: 07/19/2011

CHANGE HISTORY (before Livelink):

Initiation / Change Control Number	Revision Number	Effective Date	Change Summary
C2004-0260	00	05/03/2004	New CSOP.
C2005-0317	01	09/19/2005	 DEFINITIONS: DEA "Agency" changed to "Administration". "involve controlled substances, etc." changed to "enforces 21CFR, Part 1300 to end". 1.3 Change Responsibility from "Order Processing Representative" to "License Administrator". 1.4 "if warranted" added to action. 1.11 "determine next level of communication" replaced with "be responsible for reporting the order to the Drug Enforcement Administration." 1.12 Change Responsibility from "Order Processing Representative" to "License Administrator".

CHANGE HISTORY (in Livelink):


Livelink Workflow ID	Revision Number	Effective Date	Change Summary
CD-6798767	02	04/07/2009	Change all reference of Licensing Administrator Title to: Master Data Administrator Change all reference of CTMAN 080-041-CC-OPR – CTMAN 080-023-CC-OPR. 1.2 The SOMS Multiplier Table is determined by the Controlled Substance Compliance Department. – Delete "Call Center Management"
			1.3 "Order Processing will generate a Suspicious Order Controlled Drug (SOMS) report and email it to the License Administrator. – Change -Order Processing to Master Data Administrator – Delete" and email it to the License Administrator" 1.5 "the Supervisor or Management for review, and signature" Remove – Supervisor or.



PAGE: 4 of 5 EFFECTIVE DATE: 07/19/2011

CHANGE HISTORY (in Livelink):

Livelink Workflow ID	Revision Number	Effective Date	Change Summary
CD-8330136	03	06/12/2009	Change to Section 1.11, Upon confirmation that the order is suspicious, the Control Substance Compliance Department will be responsible for reporting the order to the Drug Enforcement Administration and the applicable State Board of Pharmacy. Department of Regulatory Affairs will also report the incident to FDA within three business days.
CD-11129819	04	See effective date in header.	Changed: SOMS Report to SOMS Form Call Center to Customer Relations Controlled Substance Compliance Dept. to DEA Affairs 1.3 – CTMAN 80-023-CC OPR, Order Processing to CTMAN 080-045 License Entry & Maintenance; Suspicious Order Controlled Drug to Suspicious Order Monitoring System.
			Added: 1.5 – if necessary 1.7 – releasing the order in full 1.9 – an order of interest or a; Orders deemed as an order of interest or as;, will be forwarded to the 1.11 – any back up documentation
			Removed: 1.9 - Determine if the order does or does not classify as suspicious.



PAGE: 5 of 5 EFFECTIVE DATE: 07/19/2011

UserName: Larry E. Shaffer (lscheffe) Title: Master Data Administrator

Date: Tuesday, 28 June 2011, 10:52 AM Pacific Time

Meaning: I have authored this document.

UserName: Sandra I. Simmons (ssimmons)

Title: Mgr, Support Services

Date: Friday, 01 July 2011, 06:41 AM Pacific Time Meaning: I have reviewed and approved this document.

UserName: Marleah M. Martin (mmartin) Title: Exec Dir, Corp Quality Assurance

Date: Monday, 11 July 2011, 01:07 PM Pacific Daylight Time

Meaning: I have reviewed and approved this document.